| Document |
Document Title |
|
WO/2023/234687A1 |
The present invention provides a method for preparing an acylic acid and/or glycolide, comprising a step of pyrolyzing a hydroxyalkanoate copolymer in the presence of a catalyst containing tin.
|
|
WO/2023/213922A1 |
The present invention primarily relates to compounds of formula (I) as defined herein. It also relates to fragrance substance mixtures as defined herein and methods for producing the same and to perfumed products as defined herein and me...
|
|
WO/2023/208121A1 |
A method of preparing a methoxy poly(ethylene glycol)-b-poly(L-lactide) (mPEG-PLLA) block copolymer is disclosed. During preparation of lactide, a mixture of antimony trioxide and phosphoric acid is used as a catalyst; at the same time, ...
|
|
WO/2023/173717A1 |
The present invention relates to a preparation method for an intermediate compound acting as a posaconazole synthetic drug, and an intermediate compound prepared thereby. The preparation method for a compound of formula (I) provided by t...
|
|
WO/2023/019244A9 |
Provided herein are compounds and their pharmaceutically acceptable salts, lipid particles comprising such compounds or pharmaceutically acceptable salts thereof and compositions of the foregoing that can be used to reduce immune intoler...
|
|
WO/2023/146244A1 |
The present disclosure provides a benzodioxane scaffold compound having AIMP2-DX2 inhibitory activity or a pharmaceutically acceptable salt thereof. The present disclosure also provides a composition comprising such a compound or a pharm...
|
|
WO/2023/131667A1 |
Embodiments of the invention are directed to cooling compounds and cooling compositions having a unique cooling perception, as well as various edible, potable, and/or cosmetic products containing one or more cooling compounds having a ge...
|
|
WO/2023/118833A1 |
1. In one aspect, a process for the preparation of vilanterol ((R)-4-(2-((6-(2-((2,6- dichlorobenzyl)oxy)ethoxy)hexyl)amino)-1-hydroxyethyl)-2-(hy
droxymethyl)phenol; Compound VI) or a pharmaceutically acceptable salt thereof, comprises ...
|
|
WO/2023/113086A1 |
The present invention relates to: a salt compound comprising a negative ion having a specific structure represented by chemical formula 1, and a positive ion represented by chemical formula 2; a quencher including the salt compound; and ...
|
|
WO/2023/110394A1 |
The present invention is directed to a process for C-H insertion by the gem-hydrogenation of an internal alkyne.
|
|
WO/2023/107877A1 |
Glycerol acetal sulfate and sulfonates, which may be used in consumer products to provide surfactant properties.
|
|
WO/2023/097690A1 |
A method for preparing a β-nitro or azido alcohol by means of high-selectivity asymmetric catalytic carbonyl reduction. The route of the method is as follows: wherein R1, R2, R3, R4 and R5 are independently selected from any one of H, h...
|
|
WO/2023/097696A1 |
Disclosed is a method for synthesizing (1R)-1-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-2-nitroethanol
. The route of the method is as follows: The method is used for synthesizing (1R)-1-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-2-nitroethanol...
|
|
WO/2023/094654A1 |
The present invention relates to polyol-derived compounds and processes preparing the same.
|
|
WO/2023/097341A2 |
Disclosed are compounds of Formula 1, including all geometric and stereoisomers, N-oxides, and salts thereof, wherein T, R1, R2, R3, R4, R5, R6, R7, W and V are as defined in the disclosure. Also disclosed are compositions containing the...
|
|
WO/2023/096111A1 |
The present application relates to a novel quinizarine derivative, wherein the quinizarine derivative has a bromodomain extra-terminal (BET) protein inhibition ability, and thus can be used in a pharmaceutical composition for preventing ...
|
|
WO/2023/083293A1 |
Provided in the present invention is a variety of pharmaceutically acceptable salts of eliglustat, comprising a napadisylate, oxalate, glutarate, mucate and various crystal forms thereof. Further provided are a pharmaceutical composition...
|
|
WO/2023/078909A1 |
The present invention relates to compounds of formula (I), a delivery system based on photoresponsive cyclic acetal or ketal compounds capable of liberating in a controlled manner active volatile carbonyl compounds into the surrounding u...
|
|
WO/2023/071865A1 |
The present invention belongs to the technical field of biodegradable materials. Disclosed are a method and a system for continuously preparing lactide by step control. The method comprises: (1) reacting a lactic acid oligomer and a depo...
|
|
WO/2023/066357A1 |
The present disclosure relates to fused cyclic compounds, preparation methods therefor, and medical uses thereof. Specifically, the present disclosure relates to the fused cyclic compound represented by general formula (I), a preparation...
|
|
WO/2023/036948A1 |
The invention pertains to a process for purifying meso-lactide which has a free acid content of at least 30 meq/kg comprising at least one step of subjecting a feed comprising at least 75 wt.% meso-lactide to solvent crystallisation foll...
|
|
WO/2023/029979A1 |
Provided is a method for preparing (S,Z)-3-(2-(4-((3,4-dichlorobenzyl)oxy)phenyl)-2,3-dihydrobe
nzo[b][1,4]dioxin-6-yl)-2-hydroxyacrylic acid and (S)-3-((S)-2-(4-((3,4-dichlorobenzyl)oxy)phenyl)-2,3-dihydro
benzo[b][1,4]dioxin-6-yl)-2-((...
|
|
WO/2023/027118A1 |
This resist composition generates an acid when being exposed to light and changes the solubility with respect to a developer through the action of the acid. The resist composition contains a compound including a cation (C0) represented b...
|
|
WO/2023/017136A1 |
A process of producing lactide from lactic acid comprises the steps of: a) feeding lactic acid, a hydrocarbon solvent and at least one catalyst into a reactor of a reactor system so as to form a reaction mixture in the reactor, b) reacti...
|
|
WO/2023/006580A1 |
The instant invention relates to thionolactone compounds useful as comonomers to introduce weak bonds for polymer degradation or functionalization. The invention is also directed to processes for the preparation of said compounds, notabl...
|
|
WO/2023/000135A1 |
Provided are new process and intermediates for preparing onapristone.
|
|
WO/2023/283523A1 |
The present disclosure generally relates to 2,3-dihydrobenzo[b][1,4]dioxin-6-yl containing compounds useful as immunomodulators. Provided herein are compounds, compositions comprising such compounds, and methods of their use. The disclos...
|
|
WO/2022/263619A1 |
The present invention relates to a vinyl keto ester and intermediates of its synthesis, wherein the vinyl moiety of the vinyl hydroxy ester and of the intermediates is partly or fully deuterated. Furthermore, the present invention relate...
|
|
WO/2022/262712A1 |
Disclosed is a method for synthesizing glycolide, which is obtained by using methyl glycolate as a raw material and by means of the following two steps of reaction: (I) (II), wherein ROH is a 18-30 carbon linear or branched alcohol, acid...
|
|
WO/2022/258792A1 |
The present invention relates to new cinnamic add amides which may be used for treatment of fibrosis and neoplasia and to cinnamic acid amides for use in the treatment of fibrosis, neoplasia, arthrolithiasis, familiar mediterranean fever...
|
|
WO/2022/260430A1 |
The present invention provides an isolation method enabling lactide racemate to be isolated in a high yield and with high efficiency without concern for side reactions even if L-lactide percentage is low.
|
|
WO/2022/255037A1 |
To provide a novel amino compound useful as an epoxy resin curing agent, a method for producing the same, etc., disclosed is an amino compound represented by formula (1) that has a quaternary carbon at the β-position of an amino group. ...
|
|
WO/2022/244715A1 |
Provided is a method for producing a 1,4-dioxane derivative represented by formula (2) and/or formula (10), including reacting water, an inorganic base, and fluoroalkene oxide represented by formula (1). Provided is a method for producin...
|
|
WO/2022/218914A1 |
The present invention refers to a process for preparing carbonyl-containing compounds of formula (Ia), (Ib) or (Ic) from Bisphenol A-based Polycarbonate and appropriate nucleophiles in the presence of imidazole or a derivative thereof as...
|
|
WO/2022/196178A1 |
To realize a method for producing glycolide that improves productivity of glycolide and suppresses generation of by-products. A method for producing glycolide that includes a first step for preparing a depolymerization reaction solution ...
|
|
WO/2022/183111A1 |
Described herein are compositions and methods for treating P. falciparum malaria by specifically activating apoptosis in cells that express PfGARP without activating apoptosis in subject host cells or parasite cells that do not express P...
|
|
WO/2022/177500A1 |
This invention relates to a method for the continuous production of optically pure lactide comprising the first reactive distillation, the second reactive distillation, the main distillation and the side-draw refluxer. For each of the fo...
|
|
WO/2022/167445A1 |
The present invention provides compounds of formula I, compositions thereof, and methods of using the same for the inhibition of GPR84, and the treatment of GPR84-mediated disorders.
|
|
WO/2022/163684A1 |
The present invention provides a modifier for resins such as polyester resins, polyester carbonate resins, and polycarbonate resins. The present invention further provides a cyclic diol compound useful as a resin modifier and a method fo...
|
|
WO/2022/158442A1 |
The present invention provides, as a radioactive halogen-labeled precursor compound that is highly stable and reactive, a compound represented by general formula (II) [in the formula, R1 and R2 each independently represent an alkyl group...
|
|
WO/2022/158993A1 |
The present invention relates to a method for the production of d-erythro-sphingosine and analogs thereof, wherein the method comprises a step of condensing a compound of formula (2): Formula (2), or a salt thereof, wherein R1 is hydroge...
|
|
WO/2022/155762A1 |
Disclosed are a preparation method for preparing lactide and a reaction device. The preparation method comprises the following steps: (1) performing the following reaction in a reactive distillation column I: subjecting lactic acid to a ...
|
|
WO/2022/139675A1 |
This invention relates to a process for the continuous production of optically pure lactide from an aqueous solution of lactic acid by means of two reactive distillations followed by a main distillation column with a side-draw refluxer. ...
|
|
WO/2022/127163A1 |
Disclosed in the present invention are a stannous salt complex catalyst and a method for producing L-lactide by using same. The catalyst is obtained by reacting stannous salt and phosphite in a solvent. The oxidation of divalent stannous...
|
|
WO/2022/123319A1 |
The present disclosure provides pharmaceutical compositions and compounds having dual agonist activity at the μ and δ opioid receptors. The agonist compounds of this disclosure can also provide GPCR functional selectivity, including se...
|
|
WO/2022/089413A1 |
The present invention provides a method for refining glycolide and glycolide obtained using same. The method comprises the steps of using a solvent A to extract impurities from crude glycolide and then using a solvent B to perform recrys...
|
|
WO/2022/076041A1 |
Tagging agents, including fluorescent monomers, which may lack polymerizable double bonds. Anti-scalant polymer compositions that include a copolymer of a tagging agent and an anti-scalant monomer. Methods for synthesizing tagging agents...
|
|
WO/2022/061091A1 |
The present invention provides an amorphous form of (S)-2-(3S,8S)-3-(4-(3,4-dichlorobenzyloxy)phenyl-7-((S)-1-ph
enylpropyl)-2,3,6,7,8,9-hexahydro-[1,4]-dioxino[2,3-g]isoqui
nolin-8-ylformylamino)-3-(4-(2,3-dimethylpyridin-4-yl)phenyl
)p...
|
|
WO/2022/052223A1 |
An intensified microinterface preparation system and method for polyglycolic acid. The intensified microinterface preparation system comprises: a hydrogenation reactor, a hydrogen feed pipe, a hydrolysis reactor, and a water vapor feed p...
|
|
WO/2022/049219A1 |
The present invention is directed to pharmaceutical compounds of formula (I), formula (l-A) and formula (l-B) and compositions thereof that can prevent or treat viral infection.
|
